In the News

ONNJ

Discussing Adneuris Therapeutics

September is Pain Awareness Month, putting an important spotlight on the millions of people living with pain and the ongoing need for better treatment options. Tris Pharma is taking a major step into the pain space with the launch of a new company focused specifically on developing innovative treatments for pain. Ketan Mehta, CEO and Founder of Tris Pharma joins the show to discuss their initiatives.

BioSpectrum Asia

Breaking the Pain-Safety Trade-Off: The Promise of Dual NOP/MOP Agonists

As Tris Pharma advances cebranopadol toward a potential FDA submission, James Hackworth discusses a novel approach designed to separate effective pain relief from the neurobiological drivers of addiction.

Discover Pharma

FDA grants orphan drug designation to Tris Pharma’s TRN-257 for idiopathic hypersomnia

FDA has granted orphan drug designation to Tris Pharma’s investigational therapy TRN-257 for the treatment of idiopathic hypersomnia, marking a regulatory milestone for the once-nightly, low-sodium oxybate candidate.

Neurology ADVISOR

Dyanavel XR Oral Suspension Now Available in 60mL Bottle Size

Dyanavel® XR (amphetamine) extended-release oral suspension, CII (2.5mg/mL) is now available through major wholesalers in a 60mL bottle size. Dyanavel XR is a central nervous system stimulant approved for the treatment of attention deficit hyperactivity disorder (ADHD) in patients aged 6 years and older. The oral suspension formulation was previously only available in a 464mL bottle.

BioTech Nation

A Euphoria-Suppressing Opioid, Ketan Mehta, Founder & CEO, Tris Pharma

On this episode of BioTech Nation…
Ever wonder what makes opioids so addictive? Moira speaks with Ketan Mehta, Founder and CEO of Tris Pharma, about opioid-induced euphoria…and an opioid that’s actually meant to suppress this response.

PharmaExec.com

Adjusting Strategies Over a 25-Year-Long Career

Tris Pharmaceutical’s founder and CEO Ketan Mehta spoke with Pharmaceutical Executive about the company’s history and how it’s adapted over the decades. While the company initially focused on oral technology, it eventually broadened its scope and is working in areas such as pain management and addiction.

Drug Delivery Leader

Increasing Oral Delivery Precision For CNS Targets With Tris Pharma’s Ketan Mehta

Videocast host Tom von Gunden talks with CEO Ketan Mehta of Tris Pharma about innovations in oral delivery approaches to CNS disorders, such as ADHD, pain, and addiction. They discuss dosage form options, including liquid, solid, and powder, for leveraging polymer-based particle science to deliver stable, long-acting formulations. Among the advances discussed is precision targeting of payload release locations in the GI tract for optimal absorption.

Contract Pharma

Tris Pharma Promotes Jim Potenziano to Chief Science and Development Officer

Tris Pharma Inc., a commercial-stage biopharmaceutical company, has promoted Jim Potenziano, Ph.D to the position of Chief Science and Development Officer (CSDO).

Patient Worthy

New Pain Medicine Seeking FDA Approval

People with rare and chronic disease often suffer from long term pain. New ways to alleviate this pain are needed. According to a press release from Tris Pharma, the results from their two Phase 3 trials showed that their study drug cebranopadol for pain, showed significant pain reduction, a strong safety profile and a lower abuse potential than oxycodone and tramadol.

Managed Healthcare Executive

Cebranopadol shows promise in phase 3 trials as a safer alternative to opioids for acute pain

Cebranopadol, a first-in-class dual NOP/MOP receptor agonist, relieves moderate-to-severe acute pain after surgery while reducing abuse risks compared with oxycodone.

FIERCE Biotech

Tris’ next-gen pain drug completes trio of clinical wins, setting up push to FDA

Tris Pharma’s opioid alternative has scored a third win in a trio of clinical trials, providing the biotech with the data needed to take the pain relief drug to the FDA this year.

Drug Topics

Cebranopadol Shows Lower Abuse Potential Compared to Existing Pain Therapies

Positive results from an intranasal human abuse potential study evaluating the intranasal pharmacokinetics and abuse potential of cebranopadol compared to oxycodone in adult nondependent recreational opioid users have been released, Tris Pharma announced in a release.

SCRIP

Tris Looks To Take On Opioids With Latest Cebranopadol Data

Tris Pharma is hoping to offer an alternative to opioid drugs for acute pain and has gotten a step closer to doing so with results from the Phase III ALLEVIATE-1 trial of cebranopadol in certain patients with postoperative pain.

FIERCE Biotech

Tris Pharma’s alternative to opioids reduces post-surgery pain in phase 3 trial ahead of NDA submission

Tris Pharma has pointed to a phase 3 win for its pain relief drug as demonstrating the candidate’s potential to help resolve the opioid crisis.

Psychiatric Times

Onyda XR: The First and Only Liquid Nonstimulant ADHD Medication

The US Food and Drug Administration (FDA) has approved Tris Pharma’s Onyda XR (clonidine hydrochloride) for the treatment of attention-deficit/hyperactivity disorder (ADHD) as a monotherapy or as an adjunctive therapy to approved central nervous system stimulant medications in pediatric patients 6 years and older.

Generics Bulletin

Cranbury Forms From Tris Pharma, With First Generic DMD Treatment Deflazacort

Tris Pharma has handed over the keys to its generics portfolio and pipeline to a new subsidiary, Cranbury Pharmaceuticals, which has debuted competition to PTC Therapeutics’ Emflaza (deflazacort) oral suspension.

Additude

Onyda XR: New FDA-Approved Liquid Non-Stimulant for ADHD

Onyda XR (clonidine hydrochloride), the first and only liquid non-stimulant ADHD medication approved in the U.S., and the only such medication with nighttime dosing, became available nationwide for the treatment of attention deficit hyperactivity disorder (ADHD) on October 1.

Biopharma dive

Tris to ask for approval of dual-acting pain drug

Positive data from a pair of acute pain studies convinced the company that its drug, which works differently than existing medications, has a good shot at reaching market.

ROI-NJ

How N.J. company, Tris Pharma, is working to solve severe shortage of ADHD medication

A year-long shortage of ADHD medicine has created an endless loop of millions of parents searching desperately to find medication for their kids — often on a monthly basis. Monmouth Junction-based Tris Pharma is working to help.

Clinical Trials Arena

Pain points: Unsolved recruitment and trial design issues in pain clinical trials

Although pain affects millions of people worldwide, the industry is still struggling in the ongoing search for safe and effective medication.

The Bio Report

Managing Pain without Addiction

Opioid overdose, abuse, and addiction affect an estimated 3 million Americans and accounts for $35 billion in U.S. healthcare costs every year.

Life Science Leader

To America, A New Biopharma Model

Ketan Mehta, founder and CEO of Tris Pharma. Mehta came to the U.S. in the late 1970s. Since then, he has built a career in pharma and, more recently, an entirely new company with a triad of businesses-platform technology licensing, generic medicines, and new drug development.

SLEEP REVIEW

How to Navigate the Narcolepsy Pharmacotherapy LandscapeManaging Pain without Addiction

With new narcolepsy drugs available, sleep specialists face the challenge of selecting the most suitable therapies for their patients.

NJBIZ Conversations: Ketan Mehta

Tris Pharma founder and CEO Ketan Mehta talks about his company’s work on a new, non-addictive pain treatment and other promising products in the pipeline.